Marinus Pharmaceuticals Inc. (MRNS) Financial Statements (2026 and earlier)

Company Profile

Business Address 5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:64,676113,300150,300176,356175,336199,201
Cash and cash equivalent64,676104,253120,572140,437127,787146,904
Short-term investments  9,00029,71635,91947,54952,297
Other undisclosed cash, cash equivalents, and short-term investments  4712   
Receivables3,4353,5133,7994,2815,23411,693
Inventory, net of allowances, customer advances and progress billings4,8735,7832,4132,7362,67437
Inventory4,8735,7832,4132,7362,67437
Other undisclosed current assets8,8988,6808,73411,66711,3659,064
Total current assets:81,882131,276165,246195,040194,609219,995
Noncurrent Assets
Operating lease, right-of-use asset 700     
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization3,7203,7353,8433,9093,9384,037
Other noncurrent assets1,4812,3391,8191,8572,6532,785
Other undisclosed noncurrent assets (700)     
Total noncurrent assets:5,2016,0745,6625,7666,5916,822
TOTAL ASSETS:87,083137,350170,908200,806201,200226,817
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21,46824,84626,86220,95420,19720,193
Accounts payable6,2376,1254,0032,6262,3024,466
Accrued liabilities15,23118,72122,85918,32817,89515,727
Debt11,55015,40111,5517,7003,850 
Restructuring reserve 952     
Other undisclosed current liabilities1,8972,5112,2111,9011,5561,321
Total current liabilities:35,86742,75840,62430,55525,60321,514
Noncurrent Liabilities
Long-term debt and lease obligation45,07558,07261,42364,78368,13671,498
Long-term debt, excluding current maturities45,07558,07261,42364,78368,13671,498
Liabilities, other than long-term debt 4221,1641,4181,7752,1462,581
Accounts payable and accrued liabilities 2115827859711,1561,411
Operating lease, liability 2115826338049901,170
Other undisclosed noncurrent liabilities53,06451,79050,67849,15647,97646,139
Total noncurrent liabilities:98,561111,026113,519115,714118,258120,218
Total liabilities:134,428153,784154,143146,269143,861141,732
Equity
Equity, attributable to parent(47,345)(16,434)16,76554,53757,33985,085
Preferred stock      4,043
Common stock555555555150
Additional paid in capital599,023594,106588,656584,710554,587546,169
Accumulated other comprehensive income (loss)   (20)(71)(114)74
Accumulated deficit(646,423)(610,595)(571,926)(530,157)(497,185)(465,251)
Total equity:(47,345)(16,434)16,76554,53757,33985,085
TOTAL LIABILITIES AND EQUITY:87,083137,350170,908200,806201,200226,817

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues8,0567,6797,1907,3386,08110,380
Cost of revenue(1,535)(756)(387)(455)(386)(206)
Gross profit:6,5216,9236,8036,8835,69510,174
Operating expenses(38,757)(42,744)(42,240)(38,529)(37,134)(43,137)
Operating loss:(32,236)(35,821)(35,437)(31,646)(31,439)(32,963)
Nonoperating income1,0251,6471,9662,9162,1752,608
Investment income, nonoperating1,1091,6111,7471,8952,1282,571
Other nonoperating income (expense)(84)362191,0214737
Interest and debt expense(4,617)(4,346)(4,298)(4,242)(4,208)(4,147)
Loss from continuing operations before equity method investments, income taxes:(35,828)(38,520)(37,769)(32,972)(33,472)(34,502)
Other undisclosed loss from continuing operations before income taxes   (4,000)   
Loss from continuing operations before income taxes:(35,828)(38,520)(41,769)(32,972)(33,472)(34,502)
Income tax benefit     1,538 
Loss from continuing operations:(35,828)(38,520)(41,769)(32,972)(31,934)(34,502)
Other undisclosed net loss  (149)   (228)
Net loss available to common stockholders, diluted:(35,828)(38,669)(41,769)(32,972)(31,934)(34,730)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(35,828)(38,669)(41,769)(32,972)(31,934)(34,730)
Comprehensive loss:(35,828)(38,669)(41,769)(32,972)(31,934)(34,730)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  205143(188)74
Comprehensive loss, net of tax, attributable to parent:(35,828)(38,649)(41,718)(32,929)(32,122)(34,656)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: